Table 1 Patient and treatment characteristics and outcomes (N=89)
Variable | All patients (N=89) | TKI exposure (n=55) | TKI non-exposure (n=34) |
|---|---|---|---|
Patient gender (female/male) | 36 (40%)/53 (60%) | 22 (40%)/33 (60%) | 14 (41%)/20 (59%) |
Age (years) at HCT: median (range) | 44 (18–62) | 45 (18–62) | 41 (20–59) |
Time (months) from diagnosis to HCT median (range) | 8.4 (1.8–125.9) | 5.5 (1.8–125.9) | 18 (3–123.1) |
Diagnosis | |||
 ALL Ph+ | 48 (54%) | 36 (65%) | 12 (35%) |
 CML | 41 (46%) | 19 (35%) | 22 (65%) |
Donor type | |||
 Matched sibling | 48 (54%) | 33 (60%) | 15 (44%) |
 Mismatched sibling | 1 (1%) | 0 (0%) | 1 (3%) |
 Matched unrelated donor | 12 (14%) | 6 (11%) | 6 (18%) |
 Mismatched unrelated donor | 28 (31%) | 16 (29%) | 12 (35%) |
Conditioning regimen | |||
 Reduced intensity | 15 (17%) | 11 (20%) | 4 (12%) |
 Myeloablative | 74 (83%) | 44 (80%) | 30 (88%) |
 Radiation-based | 59 (66%) | 40 (73%) | 19 (56%) |
 Non-radiation-based | 30 (34%) | 15 (27%) | 15 (44%) |
GVHD prophylaxis | |||
 Sirolimus/tacrolimus-based | 73 (82%) | 46 (85%) | 27 (79%) |
 Tacrolimus/methotrexate-based | 14 (16%) | 7 (11%) | 7 (21%) |
 Cyclosporine/MMF | 2 (2%) | 2 (4%) | 0 (0%) |
Time (months) to TKI start: median (range) | 1.9 (0.7–17.9) | 1.9 (0.7–17.9) | N/A |
Duration (months) of TKI exposurea: median (range) | 9.1 (0.1–89.4) | 9.1 (0.1–89.4) | N/A |
Acute GVHD | |||
 None | 36 (40%) | 24 (43%) | 12 (35%) |
 Grade I | 11 (12%) | 7 (13%) | 4 (12%) |
 Grade II | 27 (30%) | 16 (29%) | 11 (32%) |
 Grade III | 12 (14%) | 7 (13%) | 5 (15%) |
 Grade IV | 3 (4%) | 1 (2%) | 2 (6%) |
Chronic GVHD | |||
 None | 13 (14%) | 9 (16%) | 4 (12%) |
 Limited | 6 (7%) | 5 (9%) | 1 (3%) |
 Extensive | 64 (72%) | 39 (71%) | 25 (73%) |
 Died prior to day +100 | 6 (7%) | 2 (4%) | 4 (12%) |
Sclerodermatous GVHD | 15 (17%) | 8 (15%) | 7 (21%) |
 Time of onset median (months) | 16.8 (6.7–53.7) | 13.8 (10.3–33.1) | 17.1 (6.7–53.7) |
2-year OS | 72.5% (95% CI 61.8–80.7) | 73.8% (59.8–83.6) | 70.4% (51.9–82.8) |
2-year PFS | 65.9% (95% CI 54.9–74.8) | 65.1% (50.9–76.2) | 67.3% (48.7–80.4) |
2-Year relapse/progression (cumulative incidence) | 14.8% (95% CI 8.9–24.3) | 22.0% (13.3–36.2) | 3.1% (0.4–21.1) |
